Vemurafenib Terminated Phase 1 Trials for Malignant Melanoma Treatment

IndicationsStatusPurposePhase
TerminatedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01519323BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations